Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A non-seminomatous malignant germ cell tumor characterized by the presence of large germ cells with abundant cytoplasm resembling epithelial cells, geographic necrosis, high mitotic activity, and pseudoglandular and pseudopapillary structures formation. It can arise from the testis, ovary, and extragonadal sites (central nervous system and mediastinum).
Biomarker and diagnostic research for embryonal carcinoma has been reported in the published literature.
3 clinical trials registered, 3 recruiting. Interventions under study include other interventions, procedural interventions, drug therapy, and biologic therapy. Pipeline includes 1 PHASE3, 1 PHASE2. Research is primarily sponsored by academic and government institutions.
150 publications have been identified in PubMed for embryonal carcinoma. Research spans Basic Science / Preclinical (34%), Case Report / Case Series (24%), and Epidemiology / Natural History (15%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 51 |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 11:33 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
34%
Patient case studies | 36 | 24% |
Disease patterns and progression | 22 | 15% |
Research summaries | 21 | 14% |
Testing and diagnosis research | 13 | 9% |
Clinical study results | 5 | 3% |
New treatment approaches | 2 | 1% |
Khan MW (2026). [PMID: 41749828](https://pubmed.ncbi.nlm.nih.gov/41749828/). *Cancers (Basel)*. [Basic Science / Preclinical]
Honaker EC (2026). [PMID: 41870331](https://pubmed.ncbi.nlm.nih.gov/41870331/). *Int J Surg Pathol*. [Review / Meta-Analysis]
Ziade K (2026). [PMID: 41797746](https://pubmed.ncbi.nlm.nih.gov/41797746/). *Clinical case reports*. [Basic Science / Preclinical]
Janssen FW (2026). [PMID: 41998312](https://pubmed.ncbi.nlm.nih.gov/41998312/). *Commun Med (Lond)*. [Diagnostic / Biomarker]
Maharjan D (2026). [PMID: 41988850](https://pubmed.ncbi.nlm.nih.gov/41988850/). *Histopathology*. [Basic Science / Preclinical]
Pouillot W (2026). [PMID: 41881741](https://pubmed.ncbi.nlm.nih.gov/41881741/). *Ann Pathol*. [Review / Meta-Analysis]
Baccaglini W (2026). [PMID: 40952830](https://pubmed.ncbi.nlm.nih.gov/40952830/). *International braz j urol : official journal of the Brazilian Society of Urology*. [Basic Science / Preclinical]
Zanfagnin V (2026). [PMID: 41887253](https://pubmed.ncbi.nlm.nih.gov/41887253/). *Arch Pathol Lab Med*. [Diagnostic / Biomarker]
Teng P (2026). [PMID: 41959930](https://pubmed.ncbi.nlm.nih.gov/41959930/). *Case Rep Oncol Med*. [Case Report / Case Series]
Faure Conter C (2026). [PMID: 42115464](https://pubmed.ncbi.nlm.nih.gov/42115464/). *Adv Tech Stand Neurosurg*. [Review / Meta-Analysis]